Stockreport

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc.  (ANRO) 
PDF – Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 –– Completed enrollment in ALTO-203 Phase 2 proof- [Read more]